Quest Diagnostics Q3 revenue beats; raises 2026 revenue forecast

By Reuters News


Overview

  • U.S. diagnostic lab's Q3 revenue grew 10% yr/yr, beating analyst expectations

  • Adjusted EPS for Q3 rose 15.4% yr/yr, beating analyst expectations

  • Company raised full-year 2026 revenue and EPS guidance


Outlook

  • Quest Diagnostics raises 2026 revenue guidance to $12.065 bln-$12.105 bln

  • Company now expects 2026 reported diluted EPS of $10.21-$10.31

  • Company sees 2026 adjusted diluted EPS between $11.25 and $11.35


Result Drivers

  • CHANNEL GROWTH - Co said strong performance across physician, hospital and consumer channels drove Q3 results

  • ORGANIC GROWTH - Co attributed robust organic revenue growth to expanding clinical care needs of aging population and increased focus on prevention and wellness

  • AUTOMATION AND AI - Productivity gains from automation and AI contributed to Q3 performance, per CEO Jim Davis


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$3.10 bln

$3.05 bln (14 Analysts)

Q3 Adjusted EPS

Beat

$3

$2.86 (15 Analysts)

Q3 EPS

$2.78

Q3 Net Income

$312 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Quest Diagnostics Inc is $251.00, about 5.1% above its October 21 closing price of $238.93

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago


Reuters Recommended Reads

  • Oct 21 - Thermo Fisher Q3 revenue, adj profit beat estimates after new product launches

  • Oct 21 - Danaher Q3 adjusted EPS beats, FY guidance raised

  • Oct 21 - Elevance Health Q3 adjusted EPS beats estimates, raises outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.